Recent Advances In Asymmetric Organocatalytic Staudinger Synthesis Of β-lactams | 62316
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
In recent years, organocatalysts have dominated the field of asymmetric organic synthesis due to their ability to catalyze a variety of
fundamentally important transformations. One example is the Staudinger synthesis of β-lactams which continue to provide unique
opportunities for the design and synthesis of new derivatives with unprecedented biological profiles other than antibacterial activity.
In fact, during the last two decades medicinal chemists have convincingly demonstrated that structural modifications of monocyclic
β-lactams (monobactams) is an effective protocol for the discovery of new derivatives with novel pharmacological profiles. This
lecture will cover recent progress that has been made in asymmetric organocatalytic Staudinger synthesis of β-lactams since the
inaugural and pioneering investigations by Lectka and coworkers around the turn of the century, as well as our own efforts toward the
development of a novel Gilman-Speeter process for the catalytic enantioselective synthesis of β-lactams.